Inventor · disambiguated record
Patricia Vrignaud
Also filed as: VRIGNAUD PATRICIA
6 granted patents·14 pending applications·125 citations·filing 1999–2019
83Inventor score
Files withAVENTIS PHARMA SA10LEJEUNE PASCALE4AVENTIS PHARMA RORER S A1DEMERS BRIGITTE1REGENERON PHARMA1
Top patents by PatentIndex Score
20 records- 0181US8388963B2Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereofVRIGNAUD PATRICIA·Filed 2009·Granted Mar 5, 2013·7 cites·14 claims
- 0279US6342487B1Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoidAVENTIS PHARMA RORER S A·Filed 1999·Granted Jan 29, 2002·66 cites·11 claims
- 0375US7851443B2Combination comprising combretastatin and anticancer agentsAVENTIS PHARMA SA·Filed 2008·Granted Dec 14, 2010·3 cites·7 claims
- 0474US8633301B2Antitumor combinations containing antibodies recognizing specifically CD38 and vincristineLEJEUNE PASCALE·Filed 2009·Granted Jan 21, 2014·5 cites·8 claims
- 0574US6346543B1Use of a taxoid to treat abnormal cell proliferation in the brainAVENTIS PHARMA SA·Filed 1999·Granted Feb 12, 2002·42 cites·5 claims
- 0667US9259406B2Antitumor combinations containing antibodies recognizing specifically CD38 and melphalanLEJEUNE PASCALE·Filed 2009·Granted Feb 16, 2016·2 cites·12 claims
- 0753US2011305690A1Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamideLEJEUNE PASCALE·Filed 2009·Application pending·0 cites
- 0853US2013184205A1Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereofREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 0953US2019275147A1Antitumour combinations containing a vegf inhibiting agent and irinotecanAVENTIS PHARMA SA·Filed 2019·Application pending·0 cites
- 1053US2006178305A1Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereofAVENTIS PHARMA SA·Filed 2005·Application pending·0 cites
- 1152US2014350273A1Pediatric uses of cabazitaxelAVENTIS PHARMA SA·Filed 2014·Application pending·0 cites
- 1252US2014127202A1Antitumour combinations containing a vegf inhibiting agent and irinotecanAVENTIS PHARMA SA·Filed 2014·Application pending·0 cites
- 1349US2011054035A1Combination Comprising Combretastatin and Anticancer AgentsAVENTIS PHARMA SA·Filed 2010·Application pending·0 cites
- 1449US2009196869A1Antitumor combinations containing taxane derivativesSANOFI AVENTIS·Filed 2009·Application pending·0 cites
- 1548US2014056996A1Antitumoral combination comprising cabazitaxel and cisplatinAVENTIS PHARMA SA·Filed 2013·Application pending·0 cites
- 1645US2012093806A1Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabineLEJEUNE PASCALE·Filed 2009·Application pending·0 cites
- 1745US2018153931A1Antitumoral combination comprising cabazitaxel and cisplatinAVENTIS PHARMA SA·Filed 2017·Application pending·0 cites
- 1843US2010160233A1Antitumour combinations containing a vegf inhibiting agent and irinotecanAVENTIS PHARMA SA·Filed 2010·Application pending·0 cites
- 1939US2017056496A1Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamideSANOFI SA·Filed 2016·Application pending·0 cites
- 2033US2012108641A1Antitumor combination including ave8062 and sorafenibDEMERS BRIGITTE·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →